Having refreshed its coffers with a recent stock offering, Inverness continues to spend through the holiday season.
The most recent acquisition, or acquisition to be, involves BBI Holdings Plc a UK-based firm that specializes in non-invasive lateral flow diagnostics. Inverness, which already owns 12% of BBI, will pay $170 million, or $3.95 per share, for the company. The acquisition is subject to court and BBI shareholder approval.
BBI offers membrane based rapid assays, test strip manufacturing services, and, in the life science space, gold and silver nanoparticles.